Substance / Medication

Tragacanth

Overview

Active Ingredient
tragacanth
RxNorm CUI
1368197

Indications

Allergenic extracts are indicated for use in diagnostic testing and as part of a treatment regime for allergic disease, as established by allergy history and skin test reactivity. Allergenic extracts are indicated for the treatment of allergen specific allergic disease for use as hyposensitization or immunotherapy when avoidance of specific allergens can not be attained. The use of allergenic extracts for therapeutic purpose has been established by well-controlled clinical studies. Allergenic ex

Labeler: Nelco Laboratories, Inc.Updated: 2009-12-10T00:00:00.000ZFull label on DailyMed

Boxed Warning

FDA Black Box Warning

Diagnostic and therapeutic allergenic extracts are intended to be administered by a physician who is an allergy specialist and experienced in allergenic diagnostic testing and immunotherapy and the emergency care of anaphylaxis. (See Adverse Reactions) This product should not be injected intravenous

Contraindications

When this intervention should not be used

Allergenic extracts should not be used if the patient has asthma, cardiovascular disease, emphysema, diabetes, bleeding diathesis or pregnancy, unless a specific diagnosis of type 1 allergic disease is made based on skin testing and the benefits of treatment outweigh the risks of an adverse reaction

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Detailed dosage and administration information is available in the full FDA drug label.

View full prescribing information on DailyMed

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Research Evidence

Published studies and systematic reviews

Sort:
A comparative study on the emulsifying properties of various species of gum tragacanth.
Farzi Mina, Emam-Djomeh Zahra, Mohammadifar Mohammad Amin · Int J Biol Macromol · 2013
PMID: 23500441Observational
Investigation of physicochemical, morphological and biomedical properties of network hydrogels derived from arabinogalactan of acacia-tragacanth gum.
Kumar Sushil, Sharma Vikrant, Thakur Nistha et al. · Int J Biol Macromol · 2025
PMID: 39889988Other
Development of a gum tragacanth-coated nanoparticle system for controlled release of plant extracts against Erwinia amylovora.
Abadi Reyhaneh Ravanbakhshian Habib, Behbahani Mandana, Mohabatkar Hassan et al. · Int J Biol Macromol · 2025
PMID: 39805459Other
Enhancing black mulberry storage with sodium caseinate and gum tragacanth edible films.
Babaei Zahra, Moghimi Roya, Tajbakhsh Mahmood et al. · Sci Rep · 2025
PMID: 39833442OtherFull text (PMC)
Preparation of anti-leakage and salt-isolation absorbent polymer based on tragacanth gum.
Liu Panpan, Kang Yan, Li Tingli et al. · Int J Biol Macromol · 2025
PMID: 39667455Other
Exploring the potential of a pH-sensitive hydrogel sponge: interpenetrating network of tragacanth and pectin for controlled delivery of levosulpiride.
Ashraf Muhammad Umer, Iqbal Muhammad Awais, Barkat Kashif et al. · Naunyn Schmiedebergs Arch Pharmacol · 2025
PMID: 39579209Other
Dynamic borax-crosslinked transparent and antifreezing tragacanth gum-glycerol hydrogel for biomedical use.
Dadashi Pardis, Nazemi Zahra, Radmanesh Fatemeh et al. · Biomater Adv · 2026
PMID: 41317604Preclinical

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Adverse reaction and safety data for this drug is sourced from the FDA-approved label.

View adverse reactions & drug interactions on DailyMed

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Tragacanth (substance)
SNOMED CT
68524009
UMLS CUI
C0040602
RxNorm CUI
1368197
Labeler
Nelco Laboratories, Inc.

Clinical Data

This intervention maps to 1 entities in the Healos knowledge graph.

1
Conditions
0
Biomarkers
0
Specialists
0
Symptoms

Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.